{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:31:45Z","timestamp":1791156705117,"version":"4.1.0"},"reference-count":206,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2015,3,12]],"date-time":"2015-03-12T00:00:00Z","timestamp":1426118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Cancer Center Amsterdam Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neurotoxicity is a burdensome side effect of platinum-based chemotherapy that prevents administration of the full efficacious dosage and often leads to treatment withdrawal. Peripheral sensory neurotoxicity varies from paresthesia in fingers to ataxic gait, which might be transient or irreversible. Because the number of patients being treated with these neurotoxic agents is still increasing, the need for understanding the pathogenesis of this dramatic side effect is critical. Platinum derivatives, such as cisplatin and carboplatin, harm mainly peripheral nerves and dorsal root ganglia neurons, possibly because of progressive DNA-adduct accumulation and inhibition of DNA repair pathways (e.g., extracellular signal-regulated kinase 1\/2, c-Jun N-terminal kinase\/stress-activated protein kinase, and p38 mitogen-activated protein kinass), which finally mediate apoptosis. Oxaliplatin, with a completely different pharmacokinetic profile, may also alter calcium-sensitive voltage-gated sodium channel kinetics through a calcium ion immobilization by oxalate residue as a calcium chelator and cause acute neurotoxicity. Polymorphisms in several genes, such as voltage-gated sodium channel genes or genes affecting the activity of pivotal metal transporters (e.g., organic cation transporters, organic cation\/carnitine transporters, and some metal transporters, such as the copper transporters, and multidrug resistance-associated proteins), can also influence drug neurotoxicity and treatment response. However, most pharmacogenetics studies need to be elucidated by robust evidence. There are supportive reports about the effectiveness of several neuroprotective agents (e.g., vitamin E, glutathione, amifostine, xaliproden, and venlafaxine), but dose adjustment and\/or drug withdrawal seem to be the most frequently used methods in the management of platinum-induced peripheral neurotoxicity. To develop alternative options in the treatment of platinum-induced neuropathy, studies on in vitro models and appropriate trials planning should be integrated into the future design of neuroprotective strategies to find the best patient-oriented solution.<\/jats:p>","DOI":"10.1634\/theoncologist.2014-0044","type":"journal-article","created":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T01:32:49Z","timestamp":1426210369000},"page":"411-432","source":"Crossref","is-referenced-by-count":220,"title":["Platinum-Induced Neurotoxicity and Preventive Strategies: Past, Present, and Future"],"prefix":"10.1093","volume":"20","author":[{"given":"Abolfazl","family":"Avan","sequence":"first","affiliation":[{"name":"Departments of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjeerd J.","family":"Postma","sequence":"additional","affiliation":[{"name":"Departments of Neurology, VU University Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Ceresa","sequence":"additional","affiliation":[{"name":"Department of Surgery and Translational Medicine, University of Milano-Bicocca, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Avan","sequence":"additional","affiliation":[{"name":"Departments of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands"},{"name":"Department of New Sciences and Technology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Cavaletti","sequence":"additional","affiliation":[{"name":"Department of Surgery and Translational Medicine, University of Milano-Bicocca, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Giovannetti","sequence":"additional","affiliation":[{"name":"Departments of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godefridus J.","family":"Peters","sequence":"additional","affiliation":[{"name":"Departments of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,3,12]]},"reference":[{"key":"2021122309231862100_B1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2174\/1568011023353958","article-title":"Novel concepts in the development of platinum antitumor drugs","volume":"2","author":"Fuertes","year":"2002","journal-title":"Curr Med Chem Anticancer Agents"},{"key":"2021122309231862100_B2","first-page":"537","article-title":"Designing platinum compounds in cancer: Structures and mechanisms","volume":"5","author":"Boulikas","year":"2007","journal-title":"Cancer Ther"},{"key":"2021122309231862100_B3","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1039\/c3cc39258a","article-title":"Maleimide-functionalised platinum(IV) complexes as a synthetic platform for targeted drug delivery","volume":"49","author":"Pichler","year":"2013","journal-title":"Chem Commun (Camb)"},{"key":"2021122309231862100_B4","doi-asserted-by":"crossref","first-page":"296","DOI":"10.2174\/1871520611313020016","article-title":"Platinum compounds: A hope for future cancer chemotherapy","volume":"13","author":"Ali","year":"2013","journal-title":"Anticancer Agents Med Chem"},{"key":"2021122309231862100_B5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.critrevonc.2011.04.012","article-title":"Chemotherapy-induced peripheral neurotoxicity (CIPN): An update","volume":"82","author":"Argyriou","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122309231862100_B6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/jns5.12073","article-title":"Chemotherapy-induced peripheral neurotoxicity (CIPN): What we need and what we know","volume":"19","author":"Cavaletti","year":"2014","journal-title":"J Peripher Nerv Syst"},{"key":"2021122309231862100_B7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1056\/NEJM199001113220210","article-title":"Cisplatin neurotoxicity","volume":"322","author":"Mollman","year":"1990","journal-title":"N Engl J Med"},{"key":"2021122309231862100_B8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0305-7372(79)80057-2","article-title":"Cisplatin (cis-diamminedichloroplatinum II)","volume":"6","author":"Prestayko","year":"1979","journal-title":"Cancer Treat Rev"},{"key":"2021122309231862100_B9","first-page":"CD005228","article-title":"Interventions for preventing neuropathy caused by cisplatin and related compounds","volume":"3","author":"Albers","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122309231862100_B10","first-page":"CD009256","article-title":"Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer","volume":"8","author":"De Castria","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122309231862100_B11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1634\/theoncologist.9-1-8","article-title":"FDA drug approval summaries: Oxaliplatin","volume":"9","author":"Ibrahim","year":"2004","journal-title":"The Oncologist"},{"key":"2021122309231862100_B12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1158\/1535-7163.MCT-08-0840","article-title":"Platinum neurotoxicity pharmacogenetics","volume":"8","author":"McWhinney","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"suppl 15","key":"2021122309231862100_B13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0093-7754(03)00399-3","article-title":"Oxaliplatin-safety profile: Neurotoxicity","volume":"30","author":"Grothey","year":"2003","journal-title":"Semin Oncol"},{"key":"2021122309231862100_B14","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1517\/14656566.5.10.2159","article-title":"A review of oxaliplatin and its clinical use in colorectal cancer","volume":"5","author":"Grothey","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"2021122309231862100_B15","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/ene.12061","article-title":"Advanced age and liability to oxaliplatin-induced peripheral neuropathy: Post hoc analysis of a prospective study","volume":"20","author":"Argyriou","year":"2013","journal-title":"Eur J Neurol"},{"key":"2021122309231862100_B16","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/cncr.27732","article-title":"Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in 170 patients with colorectal cancer","volume":"119","author":"Argyriou","year":"2013","journal-title":"Cancer"},{"key":"2021122309231862100_B17","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/annonc\/mds208","article-title":"Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): A prospective evaluation of 150 colorectal cancer patients","volume":"23","author":"Argyriou","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122309231862100_B18","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1093\/brain\/awp219","article-title":"Oxaliplatin-induced neurotoxicity: Changes in axonal excitability precede development of neuropathy","volume":"132","author":"Park","year":"2009","journal-title":"Brain"},{"key":"2021122309231862100_B19","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1470-2045(11)70131-0","article-title":"Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics","volume":"12","author":"Cavaletti","year":"2011","journal-title":"Lancet Oncol"},{"key":"2021122309231862100_B20","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1002\/cncr.28234","article-title":"Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study","volume":"119","author":"Argyriou","year":"2013","journal-title":"Cancer"},{"key":"2021122309231862100_B21","first-page":"CD009219","article-title":"Medical interventions for the prevention of platinum-induced hearing loss in children with cancer","volume":"7","author":"Van As","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122309231862100_B22","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0022-3476(83)80551-4","article-title":"Hearing loss in children receiving cisplatin chemotherapy","volume":"102","author":"McHaney","year":"1983","journal-title":"J Pediatr"},{"key":"2021122309231862100_B23","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/01.mph.0000141348.62532.73","article-title":"Platinum compound-related ototoxicity in children: Long-term follow-up reveals continuous worsening of hearing loss","volume":"26","author":"Bertolini","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"2021122309231862100_B24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2165\/00002018-199513040-00003","article-title":"Comparative adverse effect profiles of platinum drugs","volume":"13","author":"McKeage","year":"1995","journal-title":"Drug Saf"},{"key":"2021122309231862100_B25","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djp413","article-title":"Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors","volume":"101","author":"Bryd\u00f8y","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"2021122309231862100_B26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1124\/mol.106.022244","article-title":"High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity","volume":"70","author":"Thomas","year":"2006","journal-title":"Mol Pharmacol"},{"key":"2021122309231862100_B27","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2165\/00003495-200363150-00003","article-title":"Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management","volume":"63","author":"Verstappen","year":"2003","journal-title":"Drugs"},{"key":"2021122309231862100_B28","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1186\/1471-2407-10-451","article-title":"Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability","volume":"10","author":"Hill","year":"2010","journal-title":"BMC Cancer"},{"key":"2021122309231862100_B29","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.2002.07.056","article-title":"Acute oxaliplatin-induced peripheral nerve hyperexcitability","volume":"20","author":"Wilson","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122309231862100_B30","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1158\/1078-0432.CCR-06-0694","article-title":"Oxaliplatin and axonal Na+ channel function in vivo","volume":"12","author":"Krishnan","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122309231862100_B31","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11940-010-0108-3","article-title":"Chemotherapy-induced neuropathy","volume":"13","author":"Cavaletti","year":"2011","journal-title":"Curr Treat Options Neurol"},{"key":"2021122309231862100_B32","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdt409","article-title":"Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: Two sides of the same coin","volume":"25","author":"Alberti","year":"2014","journal-title":"Ann Oncol"},{"key":"2021122309231862100_B33","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/85.14.1138","article-title":"Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data","volume":"85","author":"Brundage","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"2021122309231862100_B34","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00432-003-0524-9","article-title":"Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma","volume":"130","author":"Koeppen","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"2021122309231862100_B35","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1023\/A:1008344507482","article-title":"Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy","volume":"9","author":"Postma","year":"1998","journal-title":"Ann Oncol"},{"key":"2021122309231862100_B36","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10147-011-0298-z","article-title":"Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer","volume":"17","author":"Inoue","year":"2012","journal-title":"Int J Clin Oncol"},{"key":"2021122309231862100_B37","doi-asserted-by":"crossref","first-page":"11199","DOI":"10.1073\/pnas.1305321110","article-title":"Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2","volume":"110","author":"Sprowl","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122309231862100_B38","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1124\/jpet.111.181297","article-title":"Oxaliplatin transport mediated by organic cation\/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons","volume":"338","author":"Jong","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"2021122309231862100_B39","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/1440-1681.12088","article-title":"Evaluation of effects of copper histidine on copper transporter 1-mediated accumulation of platinum and oxaliplatin-induced neurotoxicity in vitro and in vivo","volume":"40","author":"Ip","year":"2013","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2021122309231862100_B40","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bcp.2012.10.023","article-title":"Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons","volume":"85","author":"Liu","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"2021122309231862100_B41","doi-asserted-by":"crossref","first-page":"14298","DOI":"10.1073\/pnas.162491399","article-title":"Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals","volume":"99","author":"Ishida","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122309231862100_B42","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.canlet.2005.07.046","article-title":"Role of copper transporters in the uptake and efflux of platinum containing drugs","volume":"234","author":"Safaei","year":"2006","journal-title":"Cancer Lett"},{"key":"2021122309231862100_B43","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ygyno.2005.08.046","article-title":"MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma","volume":"100","author":"Guminski","year":"2006","journal-title":"Gynecol Oncol"},{"key":"2021122309231862100_B44","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1744-8069-6-53","article-title":"Differential expression of ATP7A, ATP7B and CTR1 in adult rat dorsal root ganglion tissue","volume":"6","author":"Ip","year":"2010","journal-title":"Mol Pain"},{"key":"2021122309231862100_B45","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.bjc.6606071","article-title":"Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma","volume":"104","author":"Yamasaki","year":"2011","journal-title":"Br J Cancer"},{"key":"2021122309231862100_B46","doi-asserted-by":"crossref","first-page":"12195","DOI":"10.1021\/jp0518916","article-title":"Hydrolysis process of the second generation platinum-based anticancer drug cis-amminedichlorocyclohexylamineplatinum(II)","volume":"109","author":"Zhu","year":"2005","journal-title":"J Phys Chem B"},{"key":"2021122309231862100_B47","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/nar\/gkm032","article-title":"Mechanism of the formation of DNA-protein cross-links by antitumor cisplatin","volume":"35","author":"Chv\u00e1lov\u00e1","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"2021122309231862100_B48","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.nbd.2004.09.013","article-title":"Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: A potential mechanism for neurotoxicity","volume":"18","author":"McDonald","year":"2005","journal-title":"Neurobiol Dis"},{"key":"2021122309231862100_B49","doi-asserted-by":"crossref","first-page":"9451","DOI":"10.1523\/JNEUROSCI.0523-07.2007","article-title":"Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy","volume":"27","author":"Dzagnidze","year":"2007","journal-title":"J Neurosci"},{"key":"2021122309231862100_B50","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.neuro.2006.04.010","article-title":"Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding","volume":"27","author":"Ta","year":"2006","journal-title":"Neurotoxicology"},{"key":"2021122309231862100_B51","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1200\/JCO.1992.10.5.795","article-title":"Cisplatin neurotoxicity: The relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity","volume":"10","author":"Gregg","year":"1992","journal-title":"J Clin Oncol"},{"key":"2021122309231862100_B52","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1054\/bjoc.2001.2024","article-title":"Nucleolar damage correlates with neurotoxicity induced by different platinum drugs","volume":"85","author":"McKeage","year":"2001","journal-title":"Br J Cancer"},{"key":"2021122309231862100_B53","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1385\/BTER:74:3:223","article-title":"Toxicity of cisplatin to the central nervous system of male rabbits","volume":"74","author":"Namikawa","year":"2000","journal-title":"Biol Trace Elem Res"},{"key":"2021122309231862100_B54","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF00685034","article-title":"Direct delivery of platinum-based antineoplastics to the central nervous system: A toxicity and ultrastructural study","volume":"31","author":"Olivi","year":"1993","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122309231862100_B55","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0014-2999(00)00667-1","article-title":"The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons","volume":"406","author":"Adelsberger","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"2021122309231862100_B56","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1242\/jeb.204.4.711","article-title":"Electrophysiological analysis of the neurotoxic action of a funnel-web spider toxin, delta-atracotoxin-HV1a, on insect voltage-gated Na+ channels","volume":"204","author":"Grolleau","year":"2001","journal-title":"J Exp Biol"},{"key":"2021122309231862100_B57","doi-asserted-by":"crossref","first-page":"6704","DOI":"10.1073\/pnas.1118058109","article-title":"Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype NaV1.6-resurgent and persistent current","volume":"109","author":"Sittl","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122309231862100_B58","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00421-011-2095-9","article-title":"The spectral changes in EMG during a second bout eccentric contraction could be due to adaptation in muscle fibres themselves: A simulation study","volume":"112","author":"Dimitrov","year":"2012","journal-title":"Eur J Appl Physiol"},{"key":"2021122309231862100_B59","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.neuro.2008.09.005","article-title":"The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat","volume":"29","author":"Kagiava","year":"2008","journal-title":"Neurotoxicology"},{"key":"2021122309231862100_B60","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/1097-4598(200011)23:11<1719::AID-MUS8>3.0.CO;2-W","article-title":"Strength-duration properties and their voltage dependence as measures of a threshold conductance at the node of Ranvier of single motor axons","volume":"23","author":"Mogyoros","year":"2000","journal-title":"Muscle Nerve"},{"key":"2021122309231862100_B61","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1023\/A:1008213732429","article-title":"Oxaliplatin: A review of preclinical and clinical studies","volume":"9","author":"Raymond","year":"1998","journal-title":"Ann Oncol"},{"key":"2021122309231862100_B62","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.nbd.2010.11.017","article-title":"Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons","volume":"41","author":"Podratz","year":"2011","journal-title":"Neurobiol Dis"},{"key":"2021122309231862100_B63","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1158\/1078-0432.CCR-04-1953","article-title":"Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients","volume":"11","author":"Suk","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2021122309231862100_B64","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/CMAR.S44261","article-title":"Chemotherapy-induced peripheral neuropathy in adults: A comprehensive update of the literature","volume":"6","author":"Argyriou","year":"2014","journal-title":"Cancer Manag Res"},{"key":"2021122309231862100_B65","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00228-011-1007-6","article-title":"Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer","volume":"67","author":"Bergmann","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"2021122309231862100_B66","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1742-7843.2008.00351.x","article-title":"Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer","volume":"104","author":"Gr\u00e9en","year":"2009","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2021122309231862100_B67","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1200\/JCO.2006.10.4752","article-title":"Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: The Scottish Randomised Trial in Ovarian Cancer","volume":"25","author":"Marsh","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122309231862100_B68","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1200\/JCO.2009.21.7943","article-title":"Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: Results from North American Gastrointestinal Intergroup Trial N9741","volume":"28","author":"McLeod","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122309231862100_B69","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/tpj.2012.31","article-title":"A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil\/leucovorin\/oxaliplatin (FOLFOX4) regimen","volume":"13","author":"Cecchin","year":"2013","journal-title":"Pharmacogenomics J"},{"key":"2021122309231862100_B70","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mdt546","article-title":"Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: A GEMCAD group study","volume":"25","author":"Custodio","year":"2014","journal-title":"Ann Oncol"},{"key":"2021122309231862100_B71","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1002\/cncr.26614","article-title":"Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients","volume":"118","author":"Won","year":"2012","journal-title":"Cancer"},{"key":"2021122309231862100_B72","doi-asserted-by":"crossref","first-page":"6359","DOI":"10.1158\/1078-0432.CCR-07-0660","article-title":"Predictive factors of oxaliplatin neurotoxicity: The involvement of the oxalate outcome pathway","volume":"13","author":"Gamelin","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2021122309231862100_B73","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00280-013-2075-3","article-title":"Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer","volume":"71","author":"Lee","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122309231862100_B74","doi-asserted-by":"crossref","first-page":"729","DOI":"10.5414\/CPP48729","article-title":"Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes","volume":"48","author":"Inada","year":"2010","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2021122309231862100_B75","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ygyno.2009.01.002","article-title":"Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: A Korean population-based study","volume":"113","author":"Kim","year":"2009","journal-title":"Gynecol Oncol"},{"key":"2021122309231862100_B76","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fendo.2012.00163","article-title":"Chemotherapy refractory testicular germ cell tumor is associated with a variant in Armadillo Repeat gene deleted in Velco-Cardio-Facial syndrome (ARVCF)","volume":"3","author":"Fung","year":"2012","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2021122309231862100_B77","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00280-010-1425-7","article-title":"Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis","volume":"67","author":"Hong","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122309231862100_B78","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1200\/JCO.2009.25.2106","article-title":"Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05","volume":"28","author":"Boige","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122309231862100_B79","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejca.2008.08.011","article-title":"An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer","volume":"45","author":"Caponigro","year":"2009","journal-title":"Eur J Cancer"},{"key":"2021122309231862100_B80","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1349-7006.2009.01418.x","article-title":"Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma","volume":"101","author":"Chen","year":"2010","journal-title":"Cancer Sci"},{"key":"2021122309231862100_B81","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2008.19.1718","article-title":"Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: A study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"27","author":"Goekkurt","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122309231862100_B82","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdh319","article-title":"Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer","volume":"15","author":"Isla","year":"2004","journal-title":"Ann Oncol"},{"key":"2021122309231862100_B83","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1471-2407-8-148","article-title":"Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker","volume":"8","author":"Keam","year":"2008","journal-title":"BMC Cancer"},{"key":"2021122309231862100_B84","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/tpj.2009.45","article-title":"Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients","volume":"10","author":"Khrunin","year":"2010","journal-title":"Pharmacogenomics J"},{"key":"2021122309231862100_B85","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1200\/JCO.2006.08.1844","article-title":"Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy","volume":"25","author":"Ruzzo","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122309231862100_B86","first-page":"127","article-title":"Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI","volume":"22","author":"Seo","year":"2009","journal-title":"Oncol Rep"},{"key":"2021122309231862100_B87","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/sj.bjc.6605595","article-title":"Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): A dose-finding study and pharmacogenomic analysis","volume":"102","author":"Zarate","year":"2010","journal-title":"Br J Cancer"},{"key":"2021122309231862100_B88","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3892\/ol.2013.1467","article-title":"Polymorphisms of GSTP1, ERCC2 and TS-3\u2032UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients","volume":"6","author":"Kumamoto","year":"2013","journal-title":"Oncol Lett"},{"key":"2021122309231862100_B89","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-05-2076","article-title":"Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy","volume":"12","author":"Lecomte","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122309231862100_B90","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1479-5876-5-70","article-title":"Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-S-transferase-P1 and -M1, a retrospective cross sectional study","volume":"5","author":"Oldenburg","year":"2007","journal-title":"J Transl Med"},{"key":"2021122309231862100_B91","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/jnci\/94.12.936","article-title":"Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer","volume":"94","author":"Stoehlmacher","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2021122309231862100_B92","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/j.1468-1331.2010.02966.x","article-title":"Integrin beta-3 L33P: A new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy?","volume":"17","author":"Antonacopoulou","year":"2010","journal-title":"Eur J Neurol"},{"key":"2021122309231862100_B93","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3346\/jkms.2010.25.6.846","article-title":"Genetic polymorphism of GSTP1: Prediction of clinical outcome to oxaliplatin\/5-FU-based chemotherapy in advanced gastric cancer","volume":"25","author":"Li","year":"2010","journal-title":"J Korean Med Sci"},{"key":"2021122309231862100_B94","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.canep.2010.02.008","article-title":"Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy","volume":"34","author":"Kanai","year":"2010","journal-title":"Cancer Epidemiol"},{"key":"2021122309231862100_B95","first-page":"679","article-title":"Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer","volume":"1","author":"Booton","year":"2006","journal-title":"J Thorac Oncol"},{"key":"2021122309231862100_B96","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ejca.2008.10.015","article-title":"Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients","volume":"45","author":"Kweekel","year":"2009","journal-title":"Eur J Cancer"},{"key":"2021122309231862100_B97","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/sj.bjc.6604671","article-title":"Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin\/5-fluorouracil as first-line chemotherapy","volume":"99","author":"Par\u00e9","year":"2008","journal-title":"Br J Cancer"},{"key":"2021122309231862100_B98","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000236049","article-title":"Liability of the voltage-gated sodium channel gene SCN2A R19K polymorphism to oxaliplatin-induced peripheral neuropathy","volume":"77","author":"Argyriou","year":"2009","journal-title":"Oncology"},{"key":"2021122309231862100_B99","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/978-1-4614-4711-5_2","article-title":"Drug transporters at brain barriers: Expression and regulation by neurological disorders","volume":"763","author":"Ashraf","year":"2012","journal-title":"Adv Exp Med Biol"},{"key":"2021122309231862100_B100","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: Role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"2021122309231862100_B101","doi-asserted-by":"crossref","first-page":"572","DOI":"10.4161\/cc.4.4.1607","article-title":"CAK-cyclin-dependent activating kinase: A key kinase in cell cycle control and a target for drugs?","volume":"4","author":"Lolli","year":"2005","journal-title":"Cell Cycle"},{"key":"2021122309231862100_B102","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12017-011-8150-1","article-title":"Temporal and spatial expression of cyclin H in rat spinal cord injury","volume":"13","author":"Wu","year":"2011","journal-title":"Neuromolecular Med"},{"key":"2021122309231862100_B103","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10571-006-9095-z","article-title":"Pharmacogenomics: Catechol O-methyltransferase to thiopurine S-methyltransferase","volume":"26","author":"Weinshilboum","year":"2006","journal-title":"Cell Mol Neurobiol"},{"key":"2021122309231862100_B104","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.478","article-title":"Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy","volume":"41","author":"Ross","year":"2009","journal-title":"Nat Genet"},{"key":"2021122309231862100_B105","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/clpt.2013.80","article-title":"Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children","volume":"94","author":"Pussegoda","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"2021122309231862100_B106","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00280-013-2194-x","article-title":"Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: A systematic review and meta-analysis","volume":"72","author":"Peng","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122309231862100_B107","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ctrv.2004.12.006","article-title":"Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy","volume":"31","author":"Kweekel","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"2021122309231862100_B108","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.1007\/s13277-014-1746-y","article-title":"XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: A meta-analysis","volume":"35","author":"Zhang","year":"2014","journal-title":"Tumour Biol"},{"key":"2021122309231862100_B109","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1469-1809.2009.00549.x","article-title":"Frequency of the AGT Pro11Leu polymorphism in humans: Does diet matter?","volume":"74","author":"S\u00e9gurel","year":"2010","journal-title":"Ann Hum Genet"},{"key":"2021122309231862100_B110","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1529-8027.2007.00138.x","article-title":"Emerging role of mitogen-activated protein kinases in peripheral neuropathies","volume":"12","author":"Cavaletti","year":"2007","journal-title":"J Peripher Nerv Syst"},{"key":"2021122309231862100_B111","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ejca.2006.09.028","article-title":"Cisplatin-induced peripheral neuropathy: Neuroprotection by erythropoietin without affecting tumour growth","volume":"43","author":"Bianchi","year":"2007","journal-title":"Eur J Cancer"},{"key":"2021122309231862100_B112","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.expneurol.2006.11.010","article-title":"Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat","volume":"204","author":"Cavaletti","year":"2007","journal-title":"Exp Neurol"},{"key":"2021122309231862100_B113","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ejpain.2009.07.001","article-title":"Bortezomib-induced painful neuropathy in rats: A behavioral, neurophysiological and pathological study in rats","volume":"14","author":"Meregalli","year":"2010","journal-title":"Eur J Pain"},{"key":"2021122309231862100_B114","first-page":"7184","article-title":"Snail neurons as a possible model for testing neurotoxic side effects of antitumor agents: Paracrystal formation by Vinca alkaloids","volume":"48","author":"M\u00fcller","year":"1988","journal-title":"Cancer Res"},{"key":"2021122309231862100_B115","first-page":"963","article-title":"Quantitative ultrastructural effects of cisplatin (Platinol), carboplatin (JM8), and iproplatin (JM9) on neurons of freshwater snail Lymnaea stagnalis","volume":"52","author":"M\u00fcller","year":"1992","journal-title":"Cancer Res"},{"key":"2021122309231862100_B116","first-page":"1924","article-title":"Use of snail neurons in developing quantitative ultrastructural parameters for neurotoxic side effects of Vinca antitumor agents","volume":"50","author":"M\u00fcller","year":"1990","journal-title":"Cancer Res"},{"issue":"suppl 7","key":"2021122309231862100_B117","first-page":"82","article-title":"Neurologic protection by amifostine","volume":"26","author":"DiPaola","year":"1999","journal-title":"Semin Oncol"},{"key":"2021122309231862100_B118","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/BF01218523","article-title":"Nerve-growth-factor-dependent neurite outgrowth assay; a research model for chemotherapy-induced neuropathy","volume":"121","author":"Geldof","year":"1995","journal-title":"J Cancer Res Clin Oncol"},{"key":"2021122309231862100_B119","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1005848623771","article-title":"Vinca-alkaloid neurotoxicity measured using an in vitro model","volume":"37","author":"Geldof","year":"1998","journal-title":"J Neurooncol"},{"key":"2021122309231862100_B120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1006241622639","article-title":"In vitro protection from cisplatin-induced neurotoxicity by amifostine and its metabolite WR1065","volume":"44","author":"Verstappen","year":"1999","journal-title":"J Neurooncol"},{"key":"2021122309231862100_B121","first-page":"2337","article-title":"Amifostine protects against chemotherapy-induced neurotoxicity: An in vitro investigation","volume":"24","author":"Verstappen","year":"2004","journal-title":"Anticancer Res"},{"key":"2021122309231862100_B122","first-page":"517","article-title":"Characterization of and protection from neurotoxicity induced by oxaliplatin, bortezomib and epothilone-B","volume":"34","author":"Ceresa","year":"2014","journal-title":"Anticancer Res"},{"key":"2021122309231862100_B123","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"32","author":"Hershman","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122309231862100_B124","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/jnr.21047","article-title":"Neuroprotective effect of N-acetylcysteine on neuronal apoptosis induced by a synthetic gingerdione compound: Involvement of ERK and p38 phosphorylation","volume":"84","author":"Lin","year":"2006","journal-title":"J Neurosci Res"},{"key":"2021122309231862100_B125","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00520-013-2075-1","article-title":"Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: A randomized, double-blind, placebo-controlled trial","volume":"22","author":"Guo","year":"2014","journal-title":"Support Care Cancer"},{"key":"2021122309231862100_B126","first-page":"1117","article-title":"[Prophylactic effect of amifostine on oxaliplatin-related neurotoxicity in patients with digestive tract tumors]","volume":"27","author":"Lu","year":"2008","journal-title":"Ai Zheng"},{"key":"2021122309231862100_B127","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ygyno.2004.11.052","article-title":"A randomized phase II study of paclitaxel with carboplatin +\/\u2212 amifostine as first line treatment in advanced ovarian carcinoma","volume":"97","author":"De Vos","year":"2005","journal-title":"Gynecol Oncol"},{"key":"2021122309231862100_B128","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00520-005-0782-y","article-title":"Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin\/paclitaxel-based chemotherapy: A double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gyn\u00e4kologische Onkologoie (AGO) Ovarian Cancer Study Group","volume":"13","author":"Hilpert","year":"2005","journal-title":"Support Care Cancer"},{"key":"2021122309231862100_B129","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1385\/MO:20:3:237","article-title":"Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: A single center randomized study","volume":"20","author":"Kanat","year":"2003","journal-title":"Med Oncol"},{"key":"2021122309231862100_B130","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.2003.11.005","article-title":"Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer","volume":"21","author":"Leong","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122309231862100_B131","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/annonc\/mdg301","article-title":"Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients","volume":"14","author":"Lorusso","year":"2003","journal-title":"Ann Oncol"},{"key":"2021122309231862100_B132","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1525-1438.1999.99029.x","article-title":"Cisplatin, radiation, and amifostine in carcinoma of the uterine cervix","volume":"9","author":"Gallardo","year":"1999","journal-title":"Int J Gynecol Cancer"},{"key":"2021122309231862100_B133","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1023\/A:1008353505916","article-title":"Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer","volume":"10","author":"Planting","year":"1999","journal-title":"Ann Oncol"},{"key":"2021122309231862100_B134","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.1996.14.7.2101","article-title":"Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer","volume":"14","author":"Kemp","year":"1996","journal-title":"J Clin Oncol"},{"key":"2021122309231862100_B135","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1097\/JTO.0b013e318186fb0d","article-title":"Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303)","volume":"3","author":"Miller","year":"2008","journal-title":"J Thorac Oncol"},{"key":"2021122309231862100_B136","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/1471-2407-13-495","article-title":"Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients","volume":"13","author":"Han","year":"2013","journal-title":"BMC Cancer"},{"key":"2021122309231862100_B137","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1200\/JCO.2013.52.0536","article-title":"Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB\/Alliance)","volume":"32","author":"Loprinzi","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122309231862100_B138","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1200\/JCO.2010.31.5911","article-title":"Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7","volume":"29","author":"Grothey","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122309231862100_B139","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ejca.2010.10.006","article-title":"The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients","volume":"47","author":"Knijn","year":"2011","journal-title":"Eur J Cancer"},{"key":"2021122309231862100_B140","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s10147-009-0015-3","article-title":"Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: A prospective randomized study","volume":"15","author":"Ishibashi","year":"2010","journal-title":"Int J Clin Oncol"},{"key":"2021122309231862100_B141","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1743-7563.2010.01344.x","article-title":"Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy","volume":"6","author":"Chay","year":"2010","journal-title":"Asia Pac J Clin Oncol"},{"key":"2021122309231862100_B142","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10637-006-9010-y","article-title":"Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: Final results of a randomised, controlled, multicenter phase II study","volume":"25","author":"Von Delius","year":"2007","journal-title":"Invest New Drugs"},{"key":"2021122309231862100_B143","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.1995.13.2.490","article-title":"Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities","volume":"13","author":"Gandara","year":"1995","journal-title":"J Clin Oncol"},{"key":"2021122309231862100_B144","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1634\/theoncologist.12-3-312","article-title":"Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients","volume":"12","author":"Wang","year":"2007","journal-title":"The Oncologist"},{"key":"2021122309231862100_B145","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/cncr.28654","article-title":"North Central Cancer Treatment Group\/Alliance trial N08CA: The use of glutathione for prevention of paclitaxel\/carboplatin-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled study","volume":"120","author":"Leal","year":"2014","journal-title":"Cancer"},{"key":"2021122309231862100_B146","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/CAD.0b013e32832a2dc1","article-title":"Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: Effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity","volume":"20","author":"Milla","year":"2009","journal-title":"Anticancer Drugs"},{"key":"2021122309231862100_B147","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1200\/JCO.2002.07.061","article-title":"Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial","volume":"20","author":"Cascinu","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122309231862100_B148","first-page":"617","article-title":"Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer","volume":"112","author":"Schmidinger","year":"2000","journal-title":"Wien Klin Wochenschr"},{"key":"2021122309231862100_B149","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1023\/A:1008211226339","article-title":"Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: Results of a double-blind, randomised trial","volume":"8","author":"Smyth","year":"1997","journal-title":"Ann Oncol"},{"key":"2021122309231862100_B150","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.1995.13.1.26","article-title":"Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: A randomized double-blind placebo-controlled trial","volume":"13","author":"Cascinu","year":"1995","journal-title":"J Clin Oncol"},{"key":"2021122309231862100_B151","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1046\/j.1525-1438.1995.05020081.x","article-title":"Weekly cisplatin +\/\u2212 glutathione in relapsed ovarian carcinoma","volume":"5","author":"Colombo","year":"1995","journal-title":"Int J Gynecol Cancer"},{"key":"2021122309231862100_B152","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/BF02334967","article-title":"Evaluation by somatosensory evoked potentials of the neurotoxicity of cisplatin alone or in combination with glutathione","volume":"13","author":"Bogliun","year":"1992","journal-title":"Ital J Neurol Sci"},{"key":"2021122309231862100_B153","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00280-013-2306-7","article-title":"Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): A phase 2, multicenter, randomized, double\u2011blind, placebo\u2011controlled trial of goshajinkigan to prevent oxaliplatin\u2011induced neuropathy","volume":"72","author":"Kono","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122309231862100_B154","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s10147-010-0183-1","article-title":"The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen","volume":"16","author":"Nishioka","year":"2011","journal-title":"Int J Clin Oncol"},{"key":"2021122309231862100_B155","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s002800050723","article-title":"Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin","volume":"41","author":"Cassidy","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122309231862100_B156","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1006\/gyno.1997.4832","article-title":"A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer","volume":"67","author":"Roberts","year":"1997","journal-title":"Gynecol Oncol"},{"key":"2021122309231862100_B157","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/BF00900961","article-title":"The effects of an ACTH (4-9) analogue on development of cisplatin neuropathy in testicular cancer: A randomized trial","volume":"241","author":"Van Gerven","year":"1994","journal-title":"J Neurol"},{"key":"2021122309231862100_B158","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF00833914","article-title":"The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo","volume":"239","author":"Hovestadt","year":"1992","journal-title":"J Neurol"},{"key":"2021122309231862100_B159","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJM199001113220204","article-title":"Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer","volume":"322","author":"Van der Hoop","year":"1990","journal-title":"N Engl J Med"},{"key":"2021122309231862100_B160","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1212\/01.wnl.0000249344.99671.d4","article-title":"Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy","volume":"67","author":"Argyriou","year":"2006","journal-title":"Neurology"},{"key":"2021122309231862100_B161","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2362.2005.01467.x","article-title":"Retinoic acid increases tissue and plasma contents of nerve growth factor and prevents neuropathy in diabetic mice","volume":"35","author":"Arrieta","year":"2005","journal-title":"Eur J Clin Invest"},{"key":"2021122309231862100_B162","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1158\/1078-0432.CCR-04-1655","article-title":"A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy","volume":"11","author":"Davis","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2021122309231862100_B163","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/annonc\/mdr045","article-title":"Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: Results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial","volume":"23","author":"Durand","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122309231862100_B164","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00520-010-1018-3","article-title":"The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: Results of a randomized phase III clinical trial","volume":"19","author":"Kottschade","year":"2011","journal-title":"Support Care Cancer"},{"key":"2021122309231862100_B165","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1212\/WNL.0b013e3181d5279e","article-title":"Vitamin E neuroprotection for cisplatin neuropathy: A randomized, placebo-controlled trial","volume":"74","author":"Pace","year":"2010","journal-title":"Neurology"},{"key":"2021122309231862100_B166","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1007\/s00520-006-0072-3","article-title":"A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: Final results","volume":"14","author":"Argyriou","year":"2006","journal-title":"Support Care Cancer"},{"key":"2021122309231862100_B167","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.2003.05.139","article-title":"Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy","volume":"21","author":"Pace","year":"2003","journal-title":"J Clin Oncol"},{"issue":"suppl 18","key":"2021122309231862100_B168","doi-asserted-by":"crossref","first-page":"3507a","DOI":"10.1200\/jco.2006.24.18_suppl.3507","article-title":"Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU\/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC)","volume":"24","author":"Cassidy","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122309231862100_B169","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1158\/1078-0432.CCR-06-2289","article-title":"Sodium thiosulfate administered six hours after cisplatin does not compromise antineuroblastoma activity","volume":"14","author":"Harned","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2021122309231862100_B170","first-page":"309","article-title":"Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity","volume":"6","author":"Muldoon","year":"2000","journal-title":"Clin Cancer Res"},{"key":"2021122309231862100_B171","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1124\/jpet.105.087601","article-title":"Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels","volume":"314","author":"Dickey","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"issue":"suppl 5","key":"2021122309231862100_B172","doi-asserted-by":"crossref","first-page":"TPS10094a","DOI":"10.1200\/jco.2014.32.15_suppl.tps10094","article-title":"SIOPEL 6: A multicenter open-label randomized phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard-risk hepatoblastoma (SR-HB)","volume":"32","author":"Maibach","year":"2014","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"2021122309231862100_B173","doi-asserted-by":"crossref","first-page":"10017a","DOI":"10.1200\/jco.2014.32.15_suppl.10017","article-title":"The effects of sodium thiosulfate (STS) on cisplatin-induced hearing loss: A report from the Children's Oncology Group","volume":"32","author":"Freyer","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122309231862100_B174","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1158\/1535-7163.MCT-10-0300","article-title":"BNP7787-mediated modulation of paclitaxel- and cisplatin-induced aberrant microtubule protein polymerization in vitro","volume":"9","author":"Parker","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"2021122309231862100_B175","first-page":"90","article-title":"Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor","volume":"6","author":"De Santis","year":"2000","journal-title":"Clin Cancer Res"},{"key":"2021122309231862100_B176","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/0014-4886(95)90054-3","article-title":"Effect of nerve growth factor on peptide neurons in dorsal root ganglia after taxol or cisplatin treatment and in diabetic (db\/db) mice","volume":"132","author":"Schmidt","year":"1995","journal-title":"Exp Neurol"},{"key":"2021122309231862100_B177","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neulet.2010.09.028","article-title":"NGF protects dorsal root ganglion neurons from oxaliplatin by modulating JNK\/Sapk and ERK1\/2","volume":"486","author":"Scuteri","year":"2010","journal-title":"Neurosci Lett"},{"key":"2021122309231862100_B178","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/7214","article-title":"Nerve growth factor acts via retinoic acid synthesis to stimulate neurite outgrowth","volume":"2","author":"Corcoran","year":"1999","journal-title":"Nat Neurosci"},{"key":"2021122309231862100_B179","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.ejca.2005.04.028","article-title":"Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine","volume":"41","author":"Bianchi","year":"2005","journal-title":"Eur J Cancer"},{"issue":"suppl 1","key":"2021122309231862100_B180","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00023210-200721001-00006","article-title":"Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: A short review","volume":"21","author":"De Grandis","year":"2007","journal-title":"CNS Drugs"},{"key":"2021122309231862100_B181","first-page":"2681","article-title":"Acetyl-L-carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties","volume":"25","author":"Ghirardi","year":"2005","journal-title":"Anticancer Res"},{"key":"2021122309231862100_B182","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1016-8478(23)13316-4","article-title":"Endogenous glutamate levels regulate nerve growth factor mRNA expression in the rat dentate gyrus","volume":"7","author":"Gwag","year":"1997","journal-title":"Mol Cells"},{"key":"2021122309231862100_B183","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0531-5565(94)90062-0","article-title":"Acetyl-L-carnitine treatment increases nerve growth factor levels and choline acetyltransferase activity in the central nervous system of aged rats","volume":"29","author":"Taglialatela","year":"1994","journal-title":"Exp Gerontol"},{"key":"2021122309231862100_B184","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1158\/1078-0432.CCR-05-2177","article-title":"Protective effect of erythropoietin and its carbamylated derivative in experimental cisplatin peripheral neurotoxicity","volume":"12","author":"Bianchi","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122309231862100_B185","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1126\/science.1098313","article-title":"Derivatives of erythropoietin that are tissue protective but not erythropoietic","volume":"305","author":"Leist","year":"2004","journal-title":"Science"},{"key":"2021122309231862100_B186","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1212\/WNL.0b013e31822e045c","article-title":"Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer","volume":"77","author":"Arrieta","year":"2011","journal-title":"Neurology"},{"key":"2021122309231862100_B187","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5455\/medarh.2013.67.7-9","article-title":"Alpha lipoic acid and glycaemic control in diabetic neuropathies at type 2 diabetes treatment","volume":"67","author":"Ibrahimpasic","year":"2013","journal-title":"Med Arh"},{"key":"2021122309231862100_B188","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1002\/jnr.21722","article-title":"Hypoxia-induced deactivation of NGF-mediated ERK1\/2 signaling in hippocampal cells: Neuroprotection by acetyl-L-carnitine","volume":"86","author":"Barhwal","year":"2008","journal-title":"J Neurosci Res"},{"key":"2021122309231862100_B189","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ntt.2012.06.002","article-title":"d-Methionine protects against cisplatin-induced neurotoxicity in cortical networks","volume":"34","author":"Gopal","year":"2012","journal-title":"Neurotoxicol Teratol"},{"issue":"suppl 5","key":"2021122309231862100_B190","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1111\/j.1528-1157.1994.tb05967.x","article-title":"Oxcarbazepine: Preclinical anticonvulsant profile and putative mechanisms of action","volume":"35","author":"Schmutz","year":"1994","journal-title":"Epilepsia"},{"key":"2021122309231862100_B191","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.neuroscience.2009.02.086","article-title":"Acetyl-l-carnitine (ALCAR) prevents hypobaric hypoxia-induced spatial memory impairment through extracellular related kinase-mediated nuclear factor erythroid 2-related factor 2 phosphorylation","volume":"161","author":"Barhwal","year":"2009","journal-title":"Neuroscience"},{"key":"2021122309231862100_B192","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1200\/JCO.2012.44.8738","article-title":"Randomized double-blind placebo-controlled trial of acetyl-l-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy","volume":"31","author":"Hershman","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122309231862100_B193","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S1470-2045(06)70639-8","article-title":"Xaliproden lessens oxaliplatin-mediated neuropathy","volume":"7","author":"Susman","year":"2006","journal-title":"Lancet Oncol"},{"key":"2021122309231862100_B194","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1142\/S0192415X03000771","article-title":"Effects of goshajinkigan on corneal sensitivity, superficial punctate keratopathy and tear secretion in patients with insulin-dependent diabetes mellitus","volume":"31","author":"Nagaki","year":"2003","journal-title":"Am J Chin Med"},{"key":"2021122309231862100_B195","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/jjco\/hyp100","article-title":"Preventive effect of goshajinkigan on peripheral neurotoxicity of FOLFOX therapy: A placebo-controlled double-blind randomized phase II study (the GONE Study)","volume":"39","author":"Kono","year":"2009","journal-title":"Jpn J Clin Oncol"},{"issue":"suppl 4","key":"2021122309231862100_B196","doi-asserted-by":"crossref","first-page":"iv45","DOI":"10.1093\/neuonc\/nos203","article-title":"Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention","volume":"14","author":"Grisold","year":"2012","journal-title":"Neuro-oncol"},{"key":"2021122309231862100_B197","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s11096-013-9749-0","article-title":"Timing is important in medication administration: A timely review of chronotherapy research","volume":"35","author":"Kaur","year":"2013","journal-title":"Int J Clin Pharmacol"},{"key":"2021122309231862100_B198","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/(SICI)1097-0215(19970117)70:2<241::AID-IJC16>3.0.CO;2-L","article-title":"Circadian-system alterations during cancer processes: A review","volume":"70","author":"Mormont","year":"1997","journal-title":"Int J Cancer"},{"key":"2021122309231862100_B199","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00384-009-0838-4","article-title":"Chronomodulated chemotherapy versus conventional chemotherapy for advanced colorectal cancer: A meta-analysis of five randomized controlled trials","volume":"25","author":"Liao","year":"2010","journal-title":"Int J Colorectal Dis"},{"key":"2021122309231862100_B200","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1634\/theoncologist.2011-0343","article-title":"Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: Is it a trade-off between drug efficacy and toxicity?","volume":"16","author":"Cavaletti","year":"2011","journal-title":"The Oncologist"},{"key":"2021122309231862100_B201","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1634\/theoncologist.2011-0157","article-title":"Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: Is it a trade-off between drug efficacy and toxicity?","volume":"16","author":"Khattak","year":"2011","journal-title":"The Oncologist"},{"key":"2021122309231862100_B202","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: A randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"key":"2021122309231862100_B203","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0304-3959(02)00047-7","article-title":"Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy","volume":"98","author":"Hammack","year":"2002","journal-title":"Pain"},{"key":"2021122309231862100_B204","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/cncr.23008","article-title":"Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3)","volume":"110","author":"Rao","year":"2007","journal-title":"Cancer"},{"key":"2021122309231862100_B205","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1002\/cncr.23482","article-title":"Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled trial, N01C3","volume":"112","author":"Rao","year":"2008","journal-title":"Cancer"},{"key":"2021122309231862100_B206","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00520-010-0911-0","article-title":"A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA","volume":"19","author":"Barton","year":"2011","journal-title":"Support Care Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2014-0044","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2014-0044","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/4\/411\/41869586\/oncolo_20_4_411.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/4\/411\/41869586\/oncolo_20_4_411.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T20:37:15Z","timestamp":1717792635000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/20\/4\/411\/6399018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,12]]},"references-count":206,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,3,12]]},"published-print":{"date-parts":[[2015,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2014-0044","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,4,1]]},"published":{"date-parts":[[2015,3,12]]}}}